Beyond serotonin: newer antidepressants in the future

  title={Beyond serotonin: newer antidepressants in the future},
  author={Gopalkumar Rakesh and Chi-Un Pae and Prakash S. Masand},
  journal={Expert Review of Neurotherapeutics},
  pages={777 - 790}
ABSTRACT Introduction: There are numerous antidepressants for the treatment of major depressive disorder (MDD) on the market. However, inadequate treatment response, therapeutic lag between drug administration and the onset of clinical improvement, and safety/tolerability issues with the use of contemporary antidepressants have accelerated the search for newer antidepressants with novel mechanisms of action. Areas covered: The authors review novel antidepressants with rapid efficacy for diverse… 

International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets

It is suggested that drug targeting different neurobiological systems should be able to restore normal function but must also promote resilience to reduce the long-term vulnerability to recurrent depressive episodes.

Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System.

The most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology are discussed, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine).

The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial

It is found that scopolamine was not associated with a significantly faster antidepressant response rate compared to placebo, and the main focus of this study is to detect the capacity of the rapid-onset efficacy of such a treatment option.

"Novel Psychopharmacology for Depressive Disorders".

The present chapter briefly assesses the most promising agents, focusing on non-monoamine-targeting compounds, namely, the glutamate antagonist ketamine and its enantiomer esketamine.

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial

  • Changsu HanSheng-Min Wang A. Serretti
  • Psychology, Medicine
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2018
It is demonstrated that PGATx may be a better treatment option in the treatment of MDD in terms of effectiveness and tolerability; however, study shortcomings may limit a generalization.

Astrocytes activation contributes to the antidepressant-like effect of ketamine but not scopolamine

Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model

The observations suggest that biased agonist targeting of cortical 5-HT1A receptors constitutes a promising strategy to achieve rapid-acting and sustained antidepressant effects.

Ketamine-induced neuromuscular reactivity is associated with aging in female rhesus macaques

The incidence of ketamine-induced neuromuscular reactivity is age related but not affected by the estrous cycle in female rhesus macaques, suggesting a central nervous system (CNS) mechanism for ketamines-associated neuromUScular reactions.



Investigational drugs in recent clinical trials for treatment-resistant depression

The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future.

Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy

A small body of work to suggest ketamine might also augment electroconvulsive therapy and potentially have a role as a surgical anaesthetic in depressed patients, but there are significant practical and ethical issues about any future mainstream clinical role it might have.

Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants

The clinical effects of ketamine and its neurobiological underpinnings and mechanisms of action are summarized to provide insight into the neurobiology of depression, relevant biomarkers, and treatment targets and offer suggestions for future research that may continue to advance the field forward and ultimately improve the psychopharmacologic interventions available for those individuals struggling with depressive and trauma‐related disorders.

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

The emergence of ketamine as a fast-acting antidepressant provides promising new insights into the development of a rapid treatment response in patients with clinical depression, however, its safety and toxicity remain a concern.

Targeting of NMDA receptors in the treatment of major depression.

Recent findings concerning the role of glutamatergic signaling in the neurobiology of MDD and potential, novel therapeutic drugs, such as ketamine, memantine, AZD6765, traxoprodil, MK-0657, GLYX-13, NRX-1047, D-cycloserine, sarcosine, all of which target this system are reviewed.

Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder

The clinical evidence for glutamatergic dysfunction in MDD, the discovery and progress-to-date with ketamine as a rapidly acting antidepressant, and other glutamate receptor modulators for treatment-resistant depression are reviewed to offer potential future directions necessary to realize the enormous therapeutic promise of glutamatorgic antidepressants.

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.

No difference was observed on the study's primary outcome measure, the clinician-rated MADRS change from baseline to end of treatment, between adjunctive basimglurant MR vs placebo, and good tolerability warrant further investigation with this compound in depressive disorders.

Targeting the Glutamatergic System to Treat Major Depressive Disorder

Evidence that the glutamatergic system holds considerable promise for developing the next generation of novel and mechanistically distinct agents for the treatment of MDD is reviewed, particularly with regard to the N-methyl-D-aspartate (NMDA) antagonist ketamine as a ‘proof-of-concept’ agent.

A brief history of the development of antidepressant drugs: from monoamines to glutamate.

The noncompetitive NMDA receptor antagonist ketamine, which has consistently produced rapid and sustained antidepressant effects in MDD patients in a number of clinical studies, has shown the most promise as a novel glutamatergic-based treatment for MDD.

A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

Despite the small sample size, this pilot study suggests that an oral formulation of the NR2B antagonist MK-0657 may have antidepressant properties in TRD patients, and further studies with larger sample sizes are necessary to confirm these preliminary findings.